肝癌患者用生物免疫制剂后单核细胞及枯否细胞体外抗人肝癌细胞效应

15例肝癌患者施行外科治疗,12例兼用卡介苗、混合菌苗及干扰素,3例不用免疫治疗为对照。分离患者血单核细胞(MC)与淋巴细胞(LC)及肝枯否细胞(KC),以人肝癌细胞株为靶细胞(TC)。结果:①首次用免疫制剂7d后,MC对TC抑增殖作用及杀伤作用明显高于用药前,3次用药后MC抑TC效应提高至84％,对照组的仍为45％;②首次用药后7d,KC对TC的抑增殖率和杀伤率分别较对照组高0.5倍和1倍;③用免疫制剂后,血T细胞总数及Th数持续升高,T_s则显著下降。研究表明三联免疫制剂可有效地增强患者抗肝癌细胞的免疫功能。

IN VITRO ANTI-HEPATOMA EFFECTS OF MONOCYTES AND KUPFFER CELLS ISOLATED FROM HEPATOMA PATIENTS AFTER TREATMENT WITH IMMUNE STIMULANTS

Monooytes (MO), lymphocytes (LO) and Kupffer cells (KO) were isolated respectively from blood and surgical liver samples of 15 patients suffering from hepatoma. 13 patients were given BOG, mixed bacterium vaccine (MBV) and human white blood cell interferon (INF), the other 3 patients were not treated with any immune stimulants (IS) and served as controls. The oytostatio and cytotoxio effects of MO and KO on human hepatoma SMMO-7721 (TO) were assayed in vitro, and the numbers of T total (Tt), T helper (Th) and T suppressor (Ts) cells were counted using OKT monoclonal antibody immunofluo-rescence. The results were as follows: (1) On the 7th day after the first administration of IS, the oytostatic and oytotoxio effects of MO on TO showed obvious increase over pre-administration. The activity of IS was 1-5 times as high as in the controls. (2) After 3 administrations the oytostatio effect of MO on TO increased to the normal level (84%), while the controls remained as low as before (45%). (3) On the 7th day after first administration, cytostatic and oytotoxio effects of KO on TO were 0.5 and 1 times higher respectively than that of the controls. (4) The numbers of Tt and Th of patients given IS increased continuously; conversly, Ts decreased in number. These results indicate that combined use of BOG, MBV and INF can actively enhance the immune anti-hepatoma functions of patients suffering from hepatoma.